Researchers from Bright Peak Therapeutics AG presented the discovery and preclinical characterization of a novel first-in-class PD-1/interleukin-18 (IL-18) immunocytokine, BPT-567. A conjugatable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results